Table 2. Univariable analysis of baseline demographic characteristics and HRQOL outcomes for categorical variables.

Time point	HRQOL measure	Characteristic	Mean	95% CI	P value
Pre-treatment	FACT-G emotional	Stage IIIB	15.4	13.2–17.8	<0.01
			18.6	15.6–21.5
	MDASI distress	Female gender	3.4	1.8–5.0	0.01
			1.7	0.4–3.2
	MDASI dry mouth	Carboplatin-based chemo	2.5	0.6–4.4	0.04
			0.9	−0.1–1.8
	MDASI fatigue	Stage II/IIIA	3.4	2.2–4.5	<0.01
			1.0	−1.0–3.0
		Hemoglobin <12	3.2	−1.3–7.7	<0.01
			2.1	1.1–3.1
	MDASI numbness	Non-white ethnicity	2.3	−3.4–8.1	<0.01
			0.5	0.2–0.9
	MDASI pain	Hemoglobin <12	4.2	−1.2–9.9	<0.01
			0.5	0.2–1.1
	MDASI sadness	Age >60	3.7	1.7–4.6	0.03
			1.7	0.5–2.3
		Female gender	3.1	1.8–4.5	0.03
			1.5	0.5–2.7
	MDASI severity	Female gender	27.2	15.2–39.2	0.04
			15.2	7.5–25.9
	MDASI sleep interference	Stage II/IIIA	2.9	1.8–4.03	<0.01
			0.7	−0.3–3.2
Post-treatment	EQ-5D index value	Carboplatin-based chemo	0.7	0.3–0.9	<0.01
			0.9	0.6–1.0
	FACT-G emotional score	Female gender	16.0	12.1–19.9	0.02
			21.3	19.4–23.1
	FACT-G fatigue	Carboplatin-based chemo	2.6	1.3–3.9	0.02
			5.4	3.1–7.6
	FACT-G physical functioning	Cisplatin-based chemo	17.0	11.2–22.8	0.02
			23.1	20.1–26.1
	MDASI distress	Carboplatin-based chemo	3.0	0.5–5.5	0.04
			0.8	0.1–1.5
	MDASI dry mouth	Age >60	2.7	0.9–4.5	0.03
			0.8	−0.5–2.2
	MDASI memory	Age >60	3.2	1.5–4.9	<0.01
			0.4	−0.3–1.1
		Carboplatin-based chemo	3.6	1.5–5.8	<0.01
			0.5	−0.6–1.6
	MDASI nausea/vomiting	Non-white ethnicity	1.0	−0.8–2.1	<0.01
			0.0	0.0–0.0
	MDASI pain	Non-white ethnicity	4.3	−3.6–12.3	0.03
			1.4	−1.5–4.3
	MDASI severity	Carboplatin-based chemo	39.4	20.1–58.1	0.02
			14.9	6.2–23.6
	MDASI SOB	Hemoglobin <12	3.0	1.6–4.3	0.04
			0.0	0.0–0.0

HRQOL, health-related quality of life; FACT-G, functional assessment of cancer therapy general; MDASI, MD Anderson Symptom Inventory; SOB, shortness of breath; chemo, chemotherapy.